Skip to main content

Crown Bioscience Mengadakan Persidangan dan Pameran Dagangan AACR 2020 Maya yang Berinovatif

Written by Customer Service on . Posted in Public Companies.

SAN DIEGO, June 19, 2020 (GLOBE NEWSWIRE) — Crown Bioscience hari ini mengumumkan persidangan dan pameran dagangan AACR 2020 maya mereka yang berinovatif. Acara maya ini, yang akan berlangsung dari 22-25 Jun, akan menggabungkan semua ciri persidangan saintifik utama, dengan penceramah utama, akses kepada poster AACR 2020 CrownBio, serta reruai pameran dagangan.
Untuk seiringan dengan Mesyuarat Tahunan Maya AACR II, forum unik ini akan menampilkan penerbitan 13 poster AACR 2020 dalaman dan secara kerjasama CrownBio, meliputi pelbagai topik onkologi dan imuno-onkologi praklinikal termasuklah organoid tumor dan kejuruteraan organoid, sinergi pengimejan dan homograf tumor, serta model sasaran ubat pemanusiaan baharu, dengan pengarang poster bersedia menjawab semua soalan perwakilan.Acara ini boleh disertai secara percuma, pendaftaran diperlukan di CrownBio.com/AACR20.Sorotan daripada Keynote Theater terdiri daripada pembentangan tentang mempercepat penemuan ubat dengan organoid diterbitkan daripada pesakit (PDO) daripada Dr. Henry Li, ketua pegawai saintifik CrownBio, di samping pembentangan lanjut tentang penemuan biopenanda, penggunaan in silico untuk penemuan ubat in vitro dan platform penilaian toksikologi imunoterapi.“Kami komited untuk memajukan perbincangan saintifik dan penemuan ubat di sebalik cabaran yang kami hadapi secara global”, kata Gavin Cooper, pengarah eksekutif pemasaran di CrownBio. “Pengalaman acara inovatif kami direka bentuk untuk menyerupai pengalaman persidangan fizika sedekat yang mungkin, dengan akses langsung kepada semua sumber, poster dan pasukan saintifik kami”.Acara ini juga menampilkan Ruang Istirahat Saintifik untuk pertanyaan dan perbincangan masa nyata dengan kakitangan saintifik. Reruai Pameran Dagangan menyediakan akses kepada pelbagai sumber CrownBio, mempamerkan produk dan perkhidmatan yang merangkumi organoid, penemuan biopenanda, bioinformatik dan model xenograf diterbitkan daripada pesakit (PDX). Pendaftaran untuk acara percuma dibuka sekarang CrownBio.com/AACR20.Perihal Crown Bioscience Inc.Crown Bioscience, sebuah syarikat JSR Life Sciences, merupakan sebuah syarikat perkhidmatan penemuan dan pembangunan ubat global yang menyediakan platform translasi untuk memajukan kajian onkologi, keradangan, penyakit metabolisme. Dengan portfolio menyeluruh bagi model berkaitan dan alat ramalan, Crown Bioscience membolehkan pelanggan menyampaikan calon klinikal yang superior. Untuk mendapatkan maklumat lanjut, lawati:https://www.crownbio.comhttps://www.jsrlifesciences.comPertanyaan Media:Crown BioscienceJody Barbeaupr@crownbio.comFoto yang disertakan dengan pengumuman ini boleh didapati di https://www.globenewswire.com/NewsRoom/AttachmentNg/2e34cb8b-be2b-4be4-b596-1e33d74cd138

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.